Search hospitals > New Jersey > Hackensack
Northeast Regional Epilepsy Group
Claim this profileHackensack, New Jersey 07601
Global Leader in Epilepsy
Global Leader in Seizures
Conducts research for Partial Cycloplegia
Conducts research for Post-Implantation Syndrome
Conducts research for Myoclonic Astatic Epilepsy
33 reported clinical trials
1 medical researcher
Summary
Northeast Regional Epilepsy Group is a medical facility located in Hackensack, New Jersey. This center is recognized for care of Epilepsy, Seizures, Partial Cycloplegia, Post-Implantation Syndrome, Myoclonic Astatic Epilepsy and other specialties. Northeast Regional Epilepsy Group is involved with conducting 33 clinical trials across 18 conditions. There are 1 research doctors associated with this hospital, such as Eric Segal, M.D..Area of expertise
1Epilepsy
Global Leaderinformed consent
Legally Authorized Representative
2Seizures
Global Leaderinformed consent
Legally Authorized Representative
Top PIs
Clinical Trials running at Northeast Regional Epilepsy Group
Seizures
Epilepsy
Partial Cycloplegia
Lennox Gastaut Syndrome
Post-Implantation Syndrome
Temporal Lobe Epilepsy
Partial Seizures
Myoclonic Astatic Epilepsy
Dravet Syndrome
Pediatric Epilepsy
Cenobamate
for Focal Seizures
Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, there is little clinical data assessing its use as monotherapy in adults with POS. This study is designed to explore the effectiveness of doses of 100 mg/day and 200 mg/day as monotherapy in adult subjects with newly diagnosed or recurrent POS/focal onset epilepsy.
Recruiting3 awards Phase 41 criteria
Cenobamate
for Epilepsy
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
Recruiting2 awards Phase 312 criteria
XEN1101
for Seizures
This trial tests XEN1101, a medication added to current treatments, in people with generalized epilepsy experiencing PGTCS who are already on 1-3 anti-seizure medications. The goal is to see if taking XEN1101 with an evening meal can help reduce seizure frequency.
Recruiting1 award Phase 3
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Northeast Regional Epilepsy Group?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.